Naibec Develops Infection Prevention Agent... Technology Applied to Implants and More

[Asia Economy Reporter Jang Hyowon] Naivek, a bio-specialized company in peptide fusion technology, has obtained a patent for antimicrobial peptide-based gum (periodontal) inflammation treatment and prevention technology jointly researched with Straumann, the global No. 1 company. Based on the related patent, infection prevention products have been successfully commercialized initially, and global market sales have begun through Straumann.

Naivek announced on the 18th that it has acquired patent rights for peptide-based periodontal disease and peri-implantitis treatment and prevention technology.

This technology was applied to gingivitis, periodontitis, and peri-implantitis prevention products developed through collaboration between Straumann and Naivek. This joint research and development was achieved by transferring peptide fusion technology applicable in the dental field to Straumann in 2017, and sales are currently ongoing in the global market through Straumann.

The patent related to pharmaceutical compositions for the treatment and prevention of gingivitis, periodontitis, and peri-implantitis effectively removes bacteria, alleviates inflammation, and is characterized by easy application to implants and orthodontic devices. Based on Naivek’s proprietary anti-inflammatory and antimicrobial peptides, it also functions to block oral infections, enabling simple prevention of periodontal disease and oral infections and inflammation at home.

In particular, the company explained that the technology and product development for peri-implantitis treatment is significant as the world’s first specialized therapeutic development. Peri-implantitis is a disease with a high incidence rate to the extent that a considerable number of patients who have undergone implant procedures develop peri-implantitis (COIR Journal) as implant transplantation becomes widespread. However, no related therapeutic products have been released until now.

Unlike natural teeth, implants lack the tissue called the ‘periodontal ligament’ between the implant tooth and the gum bone, resulting in reduced bacterial infection resistance, while the absence of nerves around the implant means patients do not feel pain. It causes gum swelling, pain, bad odor, and pus formation, and if it persists for a long time, the gum bone may dissolve, causing the implant to loosen or fall out.

A Naivek official stated, “This technology is being developed through consultation with Straumann, the global No. 1 company, and infection prevention products have been successfully commercialized initially and are currently sold in the global market, with therapeutic products also under development.” He added, “Peri-implantitis is a representative side effect of implants, and developing formulations for prevention and early treatment is a meaningful achievement.”

He continued, “We expect great growth potential not only for domestic patents but also for overseas patents,” and added, “Starting with the acquisition of this technology patent, we are expanding research and development to oral preventive formulations and specialized pharmaceuticals for infection treatment, and plan to promote commercialization in the future.”

Meanwhile, Naivek has recently been attracting market attention with its platform business and pharmaceutical business based on peptides. Last year, it also showed significant growth in its cash cow-based business sector. Related sales increased by 78% compared to the previous year, and it is expected to play a supporting role in the peptide-based fusion bio research and development business, which is a future growth engine.

This content was produced with the assistance of AI translation services.